Efficacy and Safety of Nipocalimab in Sjögren’s Disease: Phase 2 Trial Results
Nipocalimab showed a significant decrease in Clinical European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index.
Read MoreNipocalimab showed a significant decrease in Clinical European League Against Rheumatism Sjögren’s Syndrome Disease Activity Index.
Read MoreIn SSc plus mild pulmonary vascular disease, early treatment with ambrisentan effectively prevented pulmonary vascular disease progress and development of PAH.
Read MoreThe following is a summary of “State of patient reported outcome measures in rheumatology,”...
Read MoreUpadacitinib 15 mg demonstrated convincing results as a treatment for giant cell arteritis in the phase 3 SELECT-GCA trial.
Read MoreA combination therapy of febuxostat and ruzinurad has been helpful for some patients with gout and hyperuricemia to reach their serum uric acid level goals.
Read More